ENLV Stock Summary and Trading Ideas (Enlivex Therapeutics Ltd. - | NASDAQ:ENLV)

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics Ltd. - trades on the NASDAQ stock market under the symbol ENLV.

As of December 11, 2024, ENLV stock price climbed to $1.28 with 130,066 million shares trading.

ENLV has a beta of 1.43, meaning it tends to be more sensitive to market movements. ENLV has a correlation of 0.02 to the broad based SPY ETF.

ENLV has a market cap of $27.40 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ENLV traded as high as $8.64 and as low as $.81.

ENLV has underperformed the market in the last year with a return of -27.3%, while the SPY ETF gained +33.7%. In the last 3 month period, ENLV fell short of the market, returning +1.0%, while SPY returned +11.2%. However, in the most recent 2 weeks ENLV has outperformed the stock market by returning +19.6%, while SPY returned +1.3%.

ENLV support price is $1.15 and resistance is $1.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENLV shares will trade within this expected range on the day.